1. Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study
- Author
-
C. Mucherino, Rocco Maurizio Zagari, Agnese Miranda, Luciana Avallone, Franco Bazzoli, Lorenzo Romano, A. Romiti, Carmelina Loguercio, Katerina Priadko, Debora Compare, Lucia Granata, Marco Martorano, Marco Romano, Antonietta Gerarda Gravina, Alessandro Federico, Concetta Tuccillo, Gerardo Nardone, Maria Raffaella Romito, D. Sgambato, Marcello Dallio, Romano, M., Gravina, A. G., Nardone, G., Federico, A., Dallio, M., Martorano, M., Mucherino, C., Romiti, A., Avallone, L., Granata, L., Priadko, K., Compare, D., Tuccillo, C., Romito, M. R., Sgambato, D., Miranda, A., Romano, L., Loguercio, C., Bazzoli, F., Zagari, R. M., Romano M., Gravina A.G., Nardone G., Federico A., Dallio M., Martorano M., Mucherino C., Romiti A., Avallone L., Granata L., Priadko K., Compare D., Tuccillo C., Romito M.R., Sgambato D., Miranda A., Romano L., Loguercio C., Bazzoli F., and Zagari R.M.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Gastroenterology ,Drug Administration Schedule ,Helicobacter Infections ,Internal medicine ,Clarithromycin ,Clarithromycin resistance ,Drug Resistance, Bacterial ,Medicine ,Humans ,Helicobacter ,antimicrobial resistance ,Adverse effect ,High prevalence ,biology ,Helicobacter pylori ,business.industry ,non-bismuth quadruple therapy ,General Medicine ,Middle Aged ,biology.organism_classification ,bacterial infections and mycoses ,Pylera ,Anti-Bacterial Agents ,Regimen ,Infectious Diseases ,Treatment Outcome ,Case-Control Studies ,Patient Compliance ,Drug Therapy, Combination ,Female ,Antacids ,business ,Life study ,Bismuth ,medicine.drug - Abstract
Background: Bismuth quadruple (BQT) and non-bismuth quadruple (N-BQT) therapies are the recommended first-line treatments for Helicobacter (H.) pylori infection. Objective: To compare the efficacy of BQT and N-BQT in clinical practice in an area with high clarithromycin resistance, choosing the regimen on the basis of previous exposure to clarithromycin. Methods: A total of 404 consecutive Hpylori-positive, naïve patients were enrolled. A total of 203 patients without previous exposure to clarithromycin received N-BQT, 100 patients for 10days and 103 for 14days, whereas 201 with previous exposure to clarithromycin received 10-day BQT. Efficacy and treatment-related adverse events were assessed. Results and Conclusions: Eradication rates by intention-to-treat analysis were 88.2% for N-BQT and 91.5% for BQT (P=.26); per-protocol analysis eradication rates were 91.2% and 95.8% for N-BQT and BQT, respectively (P=.07). Eradication rates were significantly higher with 14-day than 10-day CT (P 
- Published
- 2020